Hola,
Are you new here?

ACHILLEUS

financed

Next Generation Drug Discovery Platform for Targeting Cancer Stem Cell Pathways

Colorectal cancer (CRC) is one of the most frequent cancers with a high burden on society. In Europe alone, more than 340,000 people are diagnosed with colorectal cancer each year. While treatment options of CRC have expanded over... see more

31/10/2025

unknown leader

2M€

Project Budget: 2M€

Project leader unknown leader

PARTICIPATION DEPralty Sin fecha límite de participación.

Financing granted El organismo HORIZON EUROPE notifico la concesión del proyecto The day 2022-04-05

HORIZON-EIC-2021-TRANSITIONOPEN-01: EIC Transition Open 2021 Scope:The EIC Transition Open aims at funding innovation activities that go beyond the experimental...

I+D

Cerrada does 3 years

0% 100% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

Participantes

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 42 months Date Start: 2022-04-05
End date: 2025-10-31

Project leader unknown leader

Project Budget 2M€

participation deadline Sin fecha límite de participación.

Project description Colorectal cancer (CRC) is one of the most frequent cancers with a high burden on society. In Europe alone, more than 340,000 people are diagnosed with colorectal cancer each year. While treatment options of CRC have expanded over the last decades, the survival rates of patients suffering from advanced-stage cancers remain poor. Stemness of neoplastic cells has been proposed as a major factor in treatment resistance and high relapse rates, however, drugs targeting stem cell signaling pathways in cancer are still lacking today. We propose developing and validating a new drug discovery platform based on patient-derived organoids (PDOs) and machine learning-assisted phenotypic target validation and drug discovery. Using this platform, we have previously shown that we can identify a broad spectrum of phenotypes beyond lethality, including drug-induced changes in stemness of PDOs. As part of the EIC Open Transition project, we will validate our next-generation platform for identifying therapeutics to target stem cell signaling pathways in CRC. Based on results by us showing that an interaction of MEK and Wnt signaling shifts the balance between stemness and differentiated cells, we will target Wnt pathways as a demonstrator for the technology. The ACHILLEUS project targets critical vulnerabilities in cancer and is based on technologies and approaches developed during previous ERC Advanced and ERC Proof-of-Concept grant-funded projects. The project?s ultimate aim is to spin out a NewCo as a phenotypic drug discovery platform for targeting cancer stem cell pathways.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers